Quick Facts

• Relieves heartburn associated with acid indigestion.
• Addresses sour stomach discomfort.
• Manages symptoms related to excess stomach acid.

---

Facidex total is used to provide relief from symptoms associated with an excess of stomach acid. The therapeutic focus of this medication is the management of heartburn that is related to acid indigestion and a sour stomach. It may help manage episodes of discomfort caused by these conditions.

The inclusion of both an acid reducer and antacids allows the medication to address symptoms through different pathways. The famotidine component may help reduce acid production, while the antacid components, calcium carbonate and magnesium hydroxide, may help neutralize existing acid in the stomach.

Regulatory References

1. NIH DailyMed therapeutic overview

The eligibility profile for this medicine (likely based on Famotidine) is defined by official regulatory criteria that restrict its use based on known risk factors and patient status.

Eligibility Structure

Classification	Populations	Condition-Specific Rules
Contraindicated	Individuals with a known hypersensitivity to famotidine or other H2-receptor antagonists.	Gastric malignancy must be excluded before use for ulcers.
Conditional Use	Elderly patients; Pregnant or breastfeeding women; Pediatric patients.	Moderate to severe renal impairment (Creatinine Clearance < 60 mL/min) requires dosage adjustment.
Use Not Established	Neonates (for injection); Pediatric patients with renal impairment.	Tablet formulations are not recommended for pediatric patients weighing less than 40 kg.

Connection to the Overall Eligibility Profile

The official labeling explicitly prohibits use when a history of drug or class-related allergy exists. Use is conditional on the patient's physiological status; severe renal impairment necessitates a reduced dose to prevent toxicity, and advanced age requires increased monitoring. Finally, use in pregnant or breastfeeding populations is generally permitted only when deemed clearly necessary.

Facidex total's interaction profile is officially defined by the combined action of its H2-receptor antagonist and antacid components, resulting in pharmacokinetic interactions that alter the systemic exposure of other medicines.

These effects formally result in a decreased plasma concentration of numerous co-administered drugs. This includes certain antibiotics (e.g., Quinolones and Tetracyclines), azole antifungals (like Ketoconazole and Itraconazole), Levothyroxine, iron supplements, and Bisphosphonates. Conversely, the official labeling notes the potential for increased systemic exposure of Digoxin.

Consequently, the regulatory documentation mandates strict Administration Timing Rules to mitigate absorption interference. For most interacting oral medications, doses must be separated by at least two hours before or two hours after Facidex total administration. A stricter separation of at least four hours is required for critical drugs like Eltrombopag, a substance whose co-administration is severely restricted due to high risk of reduced exposure.

Official warnings also restrict the co-administration of Facidex total with other acid-reducing agents (such as other H2-receptor antagonists or PPIs) to prevent additive effects. Furthermore, official data identifies a population-specific consideration in elderly patients and those with renal impairment, where reduced clearance of the Famotidine component may lead to heightened risk of exposure-related adverse effects.

Facidex total works by engaging specific receptor-mediated signaling pathways to exert a localized effect on physiological processes. Its action is focused on systems where a specific paracrine mediator is responsible for escalating key secretory responses.

---

Competitive Histamine H2-Receptor Antagonism

This domain centers on the drug's role as a competitive antagonist at the H2 receptors located on the gastric parietal cells. By blocking the binding of histamine, the drug effectively suppresses the primary signal that stimulates acid production.

---

Modulation of Intracellular Signaling Cascade

The H2 receptor blockade initiates a cascade effect by inhibiting the downstream increase of cyclic AMP (cAMP) within the parietal cell. This modification of an early molecular step prevents the activation of H^+/ K^+- ATPase (the proton pump), which is the final common pathway for acid secretion.

---

Regulation of Gastric Secretion

The resulting physiological effect is a reduction in both the volume and acidity of gastric secretions. This contributes to the establishment of a state of diminished activity within the targeted pathways, which results in the limitation of the effect of excessive mediator activity (histamine) on gastric acid concentration.

Facidex total is administered via the oral route as a fixed-dose chewable tablet. Proper use requires the tablet to be chewed completely before being swallowed. The usage pattern is defined for intermittent application, intended for either the acute management of symptoms or preventative administration.

Administration Dosing and Frequency

For adult use and for children 12 years of age and older, the standard single dose is one chewable tablet. This medication is taken as needed when symptoms occur, or preemptively for prevention. When used preventatively, the tablet should be taken 10 to 60 minutes prior to the consumption of food or beverages known to trigger acid-related discomfort. The maximum amount permitted is no more than two chewable tablets in any 24-hour period.

Duration Constraints and Population Considerations

The use protocol limits the treatment duration of Facidex total to no more than 14 consecutive days. Continuation of use beyond this period requires guidance from a healthcare professional. Specific instructions govern use for certain populations. Individuals with kidney disease or those concurrently taking prescription medication are directed to ask a doctor before using the combination product. Similarly, use by children under 12 years of age requires prior consultation with a physician. These limits and consultations govern the standardized administration of the medicine.

Evidence for Use in Heartburn and Acid Indigestion

The research base for this combination medication (Famotidine, Calcium Carbonate, and Magnesium Hydroxide) has focused on its use in conditions characterized by episodic manifestations like heartburn and acid indigestion. This area was studied for outcomes related to the speed of symptom changes and the duration of acid-related effects. The majority of the evidence comes from large-scale, short-term Randomized Controlled Trials (RCTs), a study design used in research exploring how symptoms change over time.

These studies explored outcomes related to physical discomfort, such as the time interval until participants first experienced a symptom change. Researchers evaluated the proportion of people who reported adequate symptom change at defined time intervals after taking the medication. These findings describe patterns observed in the studies where the combination was associated with an earlier onset of measured symptom change than in the group receiving famotidine alone. However, the reported patterns reflected only short-term changes observed during the immediate study period.

---

Comparative Trial Data and Study Design

The evidence base includes extensive research examining the combination tablet against different comparators, including a placebo and the individual active components. These active-controlled studies were relevant in trials assessing short-term or episodic symptom patterns. For instance, research explored how the combination tablet performed compared to an antacid alone or the H2-receptor antagonist alone, focusing on outcomes describing episodic or acute changes.

In these comparison studies, data show patterns related to relief that differed from those reported by participants receiving placebo during the observation periods. Furthermore, research examined the duration of effect to see if the addition of the H2-receptor antagonist component was associated with a difference in measured symptom patterns, such as the prevention of nocturnal symptoms. These research highlights changes measured during the study period but do not provide individual predictions of outcome.

---

Assessing Long-Term Outcomes and Follow-Up Duration

Studies exploring short-term symptom changes generally involved follow-up durations that were limited, often focusing on acute relief measured within a few hours of administration. This research was relevant in trials assessing short-term or episodic symptom patterns, consistent with the typical use for conditions involving periods of heightened symptoms.

The evidence base contributes to the broader evidence landscape by providing context for how these acute responses were monitored. However, long-term effects are not fully established because the evidence is largely derived from these short-term settings. Data are still emerging for outcomes related to systemic or functional imbalance over extended periods, meaning there is limited information for long-term outcomes beyond the initial symptom observation.

---

Evidence in Specific Patient Populations

The clinical trials and regulatory evidence primarily focused on adults (individuals 18 years of age and older) who had conditions associated with acute or disruptive episodes, such as episodic heartburn. Research describes how these specific adult populations reported their perceived discomfort during the observed time intervals.

While the evidence provides context for adult use, data for certain groups remain insufficient. For example, the regulatory data are limited regarding the use of this fixed-dose combination in pediatric populations (children under 18 years of age). Therefore, the results apply only to the populations studied, and subgroup findings are uncertain regarding the applicability of these findings to children.

---

Understanding Research Gaps and Uncertainty

Despite the existence of large RCTs that provide context for acute use, several areas of uncertainty remain. Findings were mixed when comparing the combination to the antacid-only component on certain endpoints, such as preventing nocturnal awakenings in some studies.

These areas reflect the research limitations framed by the short-term focus of the available data. Evidence contributes to understanding symptom patterns, but the certainty remains low for long-term efficacy or for outcomes outside the scope of acute, intermittent use. The existing studies provide insight into short-term changes, but the follow-up durations were limited, and this area remains an evidence gap.

Common questions about Facidex total (FAQ)

---

Q: How does Facidex total differ from similar older medications?

A: Official descriptions state that this medicine is a fixed-dose combination containing both an H2-receptor antagonist and two antacids. This unique blend allows for action through two different mechanisms. The antacids are associated with immediate neutralization of stomach acid, while the H2-receptor antagonist is intended to provide more sustained acid suppression.

Q: Can Facidex total affect a person's ability to drive?

A: Regulatory documents note that Facidex total may cause Central Nervous System (CNS) effects, including dizziness, drowsiness, and confusion. These effects could potentially impact alertness and coordination. Due to these potential effects, official product information includes general warnings about engaging in activities that require mental alertness.

Q: What is the typical time frame for Facidex total to begin working?

A: This medicine is designed for a biphasic action. The antacid components are described as providing immediate acid neutralization. The second component, the H2-receptor antagonist, starts working slightly slower but is associated with a more sustained acid suppression over time.

Q: What is the listed safety profile for the use of Facidex total during pregnancy?

A: According to the official product information, Facidex total should only be used during pregnancy if clearly needed. The decision is typically made when the potential benefit is believed to outweigh the known risks to the fetus, especially since human data regarding its effects are limited.

Q: Does Facidex total affect blood pressure or heart rate?

A: Official information for the Famotidine component highlights a potential risk of QT prolongation (a change in heart rhythm). This cardiac effect is specifically noted in patient populations with pre-existing kidney problems.

Q: Can Facidex total cause changes in mood or sleep patterns?

A: Official documents list insomnia (trouble sleeping) as a potential undesirable effect. Serious Central Nervous System effects, such as confusion and hallucinations, have also been reported in regulatory data.

Q: Is Facidex total associated with any rare but serious skin reactions?

A: Regulatory labeling describes the potential for very rare but serious skin reactions. These can include conditions known as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These events are classified as severe safety concerns and necessitate immediate consultation with a healthcare provider if they are experienced.

Q: Are there any contraindications related to pre-existing heart conditions?

A: A general pre-existing heart condition is not listed as an absolute contraindication for use. However, official information indicates that use may require heightened awareness in patients with existing heart rhythm issues due to the potential risk of QT prolongation associated with the Famotidine component.

Q: Is it possible to develop a tolerance to Facidex total over time?

A: The regulatory data for H2-receptor antagonists (the drug class of one component) notes that a rapid decrease in drug response, known as tachyphylaxis, may develop. This effect is noted in regulatory data and is a pattern sometimes observed during long-term use of this class of medicine.

Q: Are there any restrictions on diet mentioned while using Facidex total?

A: Official directions mention taking the tablet preemptively prior to the consumption of food or beverages known to trigger acid-related discomfort. This is a timing instruction related to diet and use, intended to support the preventative effect of the medicine.

Q: Are weight gain or weight loss listed as possible side effects?

A: A review of the regulatory documents for this combination product indicates that weight gain or weight loss are not listed among the common or uncommon reported side effects.

Q: Is abrupt discontinuation of Facidex total mentioned in official documents?

A: The official label specifies a maximum duration for self-treatment, but the regulatory documentation does not provide specific instructions or warnings regarding the effects of abrupt discontinuation after short-term use.

Q: Does Facidex total carry any specific boxed warnings in its labeling?

A: A review of the regulatory labeling for Facidex total indicates that the combination product does not carry a Boxed Warning (sometimes called a Black Box Warning) issued by the FDA. These warnings are the strongest issued by the FDA to call attention to serious risks.

Q: Is alcohol consumption generally compatible with Facidex total?

A: The official regulatory information states that the use of alcohol should be limited or avoided. This is because alcohol is a known gastric irritant that can worsen the stomach symptoms the medicine is intended to address.

Q: Does Facidex total interact with oral contraceptives?

A: The official drug interaction list provided by regulatory authorities does not include oral contraceptives. This indicates that the combination medicine is not known to significantly alter the systemic exposure of oral contraceptives.

Q: Is there information about what to do in the event of a missed dose in the official patient leaflets?

A: Since Facidex total is intended to be taken 'as needed' when symptoms occur, or preventatively, there is no fixed dosing schedule. For this reason, the official patient information does not typically include instructions regarding what to do about a missed dose.

Q: How long does the effect of one dose of Facidex total usually last?

A: Studies related to the Famotidine component indicate that the acid-suppression effects can be measured for a period of time. This duration can last for up to 9 to 12 hours after a dose is administered.

Q: Are there any known food interactions listed for Facidex total?

A: Official information notes that the antacid components have the potential to interfere with the absorption of other medications when taken close to food. However, a detailed list of specific food items that cause problematic interactions is not provided in the regulatory documents.

Q: Does Facidex total contain common allergens like lactose or gluten?

A: The official labeling contains a complete list of both active and inactive ingredients. This full list of ingredients can be reviewed to confirm the presence or absence of substances like lactose or gluten.

Q: What regulatory body approved Facidex total for use in the United States?

A: The regulatory label and documentation for this medicine in the United States is managed by the Food and Drug Administration (FDA). This body is responsible for the formal approval of the drug for its specified uses.

Q: Do official sources describe Facidex total as having an addictive potential?

A: Official regulatory information that describes the product's safety profile does not list any potential for abuse or dependence. This is consistent with the drug class of the active ingredients.

Q: Is sun sensitivity or photosensitivity a reported side effect of Facidex total?

A: A review of the official adverse event lists for the components of Facidex total indicates that photosensitivity or increased sensitivity to the sun is not typically included among the reported side effects.

Q: What is the half-life of Facidex total?

A: According to the regulatory label, the elimination half-life of the Famotidine component is explicitly defined. In healthy adults, this is described as being approximately 2.5 to 3.5 hours.

Q: Is Facidex total considered a scheduled substance?

A: The official labeling and documentation does not classify Facidex total as a controlled substance. This means the medicine is not regulated under the Controlled Substances Act (CSA).

How to Store and Dispose of Facidex total?

This section outlines the official labeled requirements for the storage and disposal of this medicine, based strictly on government regulatory documentation for Famotidine tablets.

Mandatory Storage and Handling Conditions

Requirement	Official Instruction
Temperature	Do not store above 25 C.
Protection	Protect from both light and moisture.
Packaging	Keep the medicine in the original package.

Stability and Disposal

The product has a documented shelf-life of 3 years as packaged for sale.

Any unused medicine or waste material must be disposed of according to local requirements. Official regulatory documents state there are no special requirements for its disposal beyond adherence to local waste guidelines.